X-Pac Expandable Lumbar Cage System

K203802 · Expanding Innovations, Inc. · MAX · Jun 7, 2021 · Orthopedic

Device Facts

• Record ID: K203802
• Device Name: X-Pac Expandable Lumbar Cage System
• Applicant: Expanding Innovations, Inc.
• Product Code: MAX · Orthopedic
• Decision Date: Jun 7, 2021
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3080
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Expanding Innovations X-Pac Expandable Lumbar Cage System is indicated for use as an intervertebral body fusion device in skeletally mature patients. The system is designed for use with autogenous bone graft material to facilitate spinal fusion. The system is intended for use in patients with degenerative disc disease (defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies) at one or two contiguous levels of the lumbar spine (L2-S1). Patients should have at least 6 months of non-operative treatment prior to surgery. In addition, these patients may have up to Grade 1 spondylolisthesis at the involved level(s). These implants are used to facilitate fusion in the lumbar spine and are placed via transforaminal approach using autogenous bone graft material. The system is intended for use with supplemental fixation systems cleared for use by the FDA for use in the thoracolumbar spine.

Device Story

Lumbar interbody fusion system; consists of expandable cage implant and surgical instruments. Implant provides structural stability post-discectomy; placed via transforaminal approach. Features intraoperative adjustment for parallel or lordotic configurations; superior/inferior surface protrusions grip vertebral endplates to resist expulsion. Used by surgeons in clinical settings; requires supplemental fixation. Benefits patient by facilitating spinal fusion in degenerative disc disease cases.

Clinical Evidence

Bench testing only. Mechanical performance testing conducted per ASTM F2077 (compression, compressive shear) and ASTM F2267 (subsidence), plus expulsion testing. Results demonstrate substantial equivalence to predicate devices.

Technological Characteristics

Materials: medical grade titanium alloy (ASTM F136, ASTM F1472). Design: expandable cage with parallel/lordotic adjustment capability. Sterilization: non-sterile, requires steam sterilization. Connectivity: N/A. Energy source: N/A.

Indications for Use

Indicated for skeletally mature patients with degenerative disc disease at one or two contiguous lumbar levels (L2-S1) with up to Grade 1 spondylolisthesis or retrolisthesis. Requires 6 months prior non-operative treatment. Used with autogenous bone graft and supplemental fixation.

Regulatory Classification

Identification

An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.

Special Controls

*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.

Predicate Devices

• Expanding Innovations X-Pac Expandable Lumbar Cage System (K152539)
• Expanding Innovations X-Pac Expandable Lumbar Cage System (K160856)
• Expanding Innovations X-Pac Expandable Lumbar Cage System (K201145)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is in blue and includes the letters "FDA" followed by the words "U.S. Food & Drug Administration".

June 7, 2021

Expanding Innovations. Inc % Ms. Carolyn Guthrie Director of QA/RA Kapstone Medical, LLC 510 Elliot Street Charlotte, NC 28202

Re: K203802

Trade/Device Name: X-Pac Expandable Lumbar Cage System Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral body fusion device Regulatory Class: Class II Product Code: MAX Dated: March 8, 2021 Received: March 9, 2021

Dear Ms. Guthrie:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's

{1}------------------------------------------------

requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

Brent L. Showalter, Ph.D. Assistant Director DHT6B: Division of Spinal Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

## Indications for Use

510(k) Number (if known) K203802

Device Name X-Pac Expandable Lumbar Cage System

## Indications for Use (Describe)

The Expanding Innovations X-Pac Expandable Lumbar Cage System is indicated for use as an intervertebral body fusion device in skeletally mature patients. The system is designed for use with autogenous bone graft material to facilitate spinal fusion. The system is intended for use in patients with degenerative disc disease (defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies) at one or two contiguous levels of the lumbar spine (L2-S1). Patients should have at least 6 months of non-operative treatment prior to surgery. In addition, these patients may have up to Grade 1 spondylolisthesis at the involved level(s). These implants are used to facilitate fusion in the lumbar spine and are placed via transforaminal approach using autogenous bone graft material. The system is intended for use with supplemental fixation systems cleared for use by the FDA for use in the thoracolumbar spine.

| Type of Use (Select one or both, as applicable) | |
|-------------------------------------------------|--|
|-------------------------------------------------|--|

X Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

## CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image contains the logo for "Expanding Innovations". The word "Expanding" is in a bold, blue font, with a red dotted line arching over the word. Below "Expanding" is the word "Innovations", also in a blue font, but smaller and less bold than "Expanding". The logo is simple and clean, with a focus on the company's name.

# K203802 510(k) Summary

This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

#### A. Name, Address, Phone, and Fax Number of Applicant

Expanding Innovations, Inc. 110 Pioneer Way, Suite 1 Mountain View, CA 94041 Phone: [phone]

#### B. Contact Person

Carolyn Guthrie Director of QA/RA Kapstone Medical, LLC

#### C. Date Prepared

May 14, 2021

#### D. Device Name and Classification

| Trade Name: | Expanding Innovations X-Pac Expandable Lumbar Cage<br>System |
|----------------------|--------------------------------------------------------------|
| Common Name: | Intervertebral Body Fusion Device |
| CFR Classification: | 21 CFR§888.3080 |
| Classification Name: | Intervertebral Body Fusion Device |
| Product Code: | MAX |

#### E. Predicate Device

The Expanding Innovations X-Pac Expandable Lumbar Cage System is substantially equivalent to the previously cleared Expanding Innovations X-Pac Expandable Lumbar Cage System, K152539, K160856 and K201145.

#### F. Device Description

The Expanding Innovations X-Pac Expandable Lumbar Cage System is a lumbar interbody fusion system comprised of a cage implant and surgical instruments. The

> K203802 510k Summary Page 1 of 3

{4}------------------------------------------------

Image /page/4/Picture/1 description: The image shows the logo for "Expanding Innovations". The word "Expanding" is in blue with a red dotted arc over it. The word "Innovations" is in gray and is located under the word "Expanding".

implants are used to provide structural stability in skeletally mature individuals following discectomy and are placed via the transforaminal approach. The device is available in various sizes and footprints to accommodate varying anatomy, and is designed to allow for intraoperative adjustment in both the parallel and lordotic configurations. The implants are designed for use with autogenous bone graft material. Protrusions on the superior and inferior surfaces of each implant grip the endplates of the adjacent vertebrae to resist expulsion. The implants are manufactured from medical grade titanium alloy per ASTM F136, and ASTM F1472. The Expanding Innovations X-Pac Expandable Lumbar Cage System implants are single-use, provided non-sterile, and are intended to be cleaned and steam sterilized before use. The surgical instruments are re-usable, provided nonsterile, and are intended to be cleaned and steam sterilized before each use. Additional cage sizes are the subject of this traditional 510(k).

#### Indications for Use / Intended Use G.

The Expanding Innovations X-Pac Expandable Lumbar Cage System is indicated for use as an intervertebral body fusion device in skeletally mature patients. The system is designed for use with autogenous bone graft material to facilitate spinal fusion.

The system is intended for use in patients with degenerative disc disease (defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies) at one or two contiguous levels of the lumbar spine (L2-S1). Patients should have at least 6 months of non-operative treatment prior to surgery. In addition, these patients may have up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s). These implants are used to facilitate fusion in the lumbar spine and are placed via transforaminal approach using autogenous bone graft material. The system is intended for use with supplemental fixation systems cleared for use by the FDA for use in the thoracolumbar spine.

{5}------------------------------------------------

Image /page/5/Picture/0 description: The image shows the logo for Expanding Innovations. The word "Expanding" is in blue, with a red dotted line arching over it. Below "Expanding" is the word "Innovations" in a smaller, gray font. The logo is simple and modern.

#### H. Technological Comparison

The technological characteristics of the Expanding Innovations X-Pac Expandable Lumbar Cage System implants are substantially equivalent to the predicate in terms of intended use, indications for use, overall design, function, technology, materials, and performance.

#### l. Performance Data

A risk assessment, including mechanical testing, was conducted to confirm that the new cage sizes do not introduce new issues of safety or effectiveness. The new cage sizes successfully underwent performance testing including verification and validation testing and mechanical testing in accordance with ASTM F2077 for compression and compressive shear paradigms; ASTM F2267 for subsidence testing; and expulsion testing. The mechanical performance tests were based on well-recognized test methods for interbody fusion devices, including those outlined in Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Intervertebral Body Fusion Device. Test results demonstrate substantial equivalence to the predicate device.

#### J. Basis for Substantial Equivalence

The modified X-Pac Expandable Lumbar Cage System is identical to the predicate with respect to intended use, indications for use, overall design, function, technology, materials, and performance as well as procedural steps, surgical instrumentation, and product labeling. The information provided supports the substantial equivalence of the modified X-Pac Expandable Lumbar Cage System to the leqally marketed predicate devices.